Posted by Michael Wonder on 17 Jun 2021
Expanded PBS listing to save Australians around $120,000 a year
17 June 2021 - More than 800 Australians with stage IV advanced or metastatic kidney cancer will now have improved access to a heavily subsidised treatment through an expanded listing on the PBS.
From 1 July 2021, Cabometyx (cabozantinib), will now be available as a first-line treatment for Australians with stage IV clear cell variant renal cell carcinoma.
It has been available as a second-line treatment for patients with advanced renal cell carcinoma since 2018.
